ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1247

Lung Ultrasound in Patients with Connective Tissue Disease-associated Interstitial Lung Disease; Utility of Single Evaluation in Clinical Practice

Shinji Watanabe1, Keina Yomono2, Mikito Suzuki2, Nobuhito Sasaki2, Takahisa Gono2 and Masataka Kuwana2, 1Nippon Medical School Graduate School of Medicine, Bunkyo-ku, Tokyo, Japan, 2Nippon Medical School Graduate School of Medicine, Tokyo, Japan

Meeting: ACR Convergence 2022

Keywords: interstitial lung disease, Ultrasound

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2022

Title: Imaging of Rheumatic Diseases Poster

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: Utility of lung ultrasound (LUS) in evaluation of interstitial lung disease (ILD) has recently attracted attention because of handiness and low invasiveness. The majority of previous reports dealt with systemic sclerosis (SSc)-associated ILD, while it remains unclear how to apply LUS to clinical practice of connective tissue disease (CTD)-associated ILD (CTD-ILD). Using a prospective registry of LUS, we examined i) whether LUS can be a substitute for a prognostic indicator (ILD extent) obtained by high-resolution CT (HRCT) and ii) whether LUS has additional benefits to information obtained from HRCT.

Methods: Patients with CTD-ILD who underwent HRCT and LUS simultaneously were selected from a single-center prospective registry of LUS, based on satisfaction of at least one of classification criteria for idiopathic inflammatory myopathy (IIM), anti-synthetase antibody syndrome (ASS), SSc, rheumatoid arthritis (RA), or mixed connective tissue disease (MCTD); and ILD confirmed by HRCT. Total B-lines were assessed using a 4-8 MHz microconvex transducer at 14 scanning sites. ILD extent on HRCT was semi-quantitatively assessed using an average of five sections according to Goh et al. We used modified MRC dyspnea scale, serum KL-6 and SP-D, forced vital capacity (FVC), diffusing lung capacity for carbon monoxide (DLCO), HRCT pattern, 6-minute walk test (6MWT) parameters, and GAP index as severity or prognostic parameters. Correlations were assessed using a single regression model with Pearson’s correlation coefficient (r). Multiple regression analysis was conducted to evaluate additional value of LUS in conjunction with information obtained from chest HRCT.

Results: This study enrolled 67 patients, including 29 with IIM/ASS, 25 with SSc, 10 with RA, and 3 with MCTD. LUS total B-lines and ILD extent on HRCT were correlated with each other (r = 0.66, P < 0.001). When the correlations between these indices were examined in individual CTDs, SSc showed better correlation, compared with IIM/ASS (Figure 1), while there was no difference in the correlations among patients with different HRCT morphologic patterns (Figure 2). LUS total B-lines and ILD extent on HRCT correlated individually with modified MRC dyspnea scale, serum KL-6, FVC, DLCO, minimum SpO2 during 6MWT and GAP index, although the correlation coefficient tended to be better for HRCT (Table 1). Multiple regression analysis revealed that there was no improvement of the correlations of ILD extent on HRCT with severity/prognostic markers by incorporating LUS total B-lines as covariates.

Conclusion: LUS total B-lines were generally correlated with the ILD extent on HRCT in patients with CTD-ILD, especially in those with SSc-ILD. LUS total B-lines were correlated with many ILD severity/prognostic parameters, but we failed to demonstrate no additive role of LUS on top of HRCT at least in a single evaluation.

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: S. Watanabe, None; K. Yomono, None; M. Suzuki, None; N. Sasaki, None; T. Gono, Astellas, Asahi Kasei, Boehringer Ingelheim, Bristol Myers Squibb, Chugai, Daiichi Sankyo, Eli Lilly, Janssen, Mitsubishi Tanabe, Ono Pharmacetuicals; M. Kuwana, Boehringer-Ingelheim, Ono pharmaceuticals, Mochida, AbbVie/Abbott, Astellas, Janssen, Bayer, Corbus, Horizon.

To cite this abstract in AMA style:

Watanabe S, Yomono K, Suzuki M, Sasaki N, Gono T, Kuwana M. Lung Ultrasound in Patients with Connective Tissue Disease-associated Interstitial Lung Disease; Utility of Single Evaluation in Clinical Practice [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/lung-ultrasound-in-patients-with-connective-tissue-disease-associated-interstitial-lung-disease-utility-of-single-evaluation-in-clinical-practice/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/lung-ultrasound-in-patients-with-connective-tissue-disease-associated-interstitial-lung-disease-utility-of-single-evaluation-in-clinical-practice/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology